May 2025 in “The Journal of Rheumatology” This study reports that even minimal improvements in SLE-related fatigue and skin symptoms are meaningful to patients, supporting the content validity of the FACIT-Fatigue scale for measuring these effects.
May 2024 in “JEADV Clinical Practice” In this study, researchers found that among patients with severe alopecia areata, a change in SALT scores of 42 or 43 points represents meaningful improvement, highlighting the need to consider individual treatment goals beyond conventional low SALT score targets when assessing treatment benefits.
September 2022 in “Journal of Investigative Dermatology” This study found that the Severity of Alopecia Tool score does not predict the quality of life in patients with alopecia areata, suggesting patient-reported outcomes better reflect the impact on life quality.
November 2025 in “SKIN The Journal of Cutaneous Medicine” This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.
3 citations
,
March 2025 in “Journal of Clinical Medicine” This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.